Clinical Trial for Low Grade (Grade II) Glioma Patients Now Open and Accepting Patients
Miles For Hope announced today that the brain tumor vaccine clinical trial, Optimizing Dendritic Cell Vaccination for Low Grade Glioma Patients, is now open and accepting new patients. Patients must have a Grade II Brain Tumor and surgery at UCLA to qualify for the trial. The trial is a Phase II Clinical Trial Evaluating Autologous Dendritic Cells Pulsed with Tumor Lysate Antigen for the Treatment of Low-grade Gliomas.
This clinical trial was proudly funded by Miles For Hope, Accelerate Brain Cancer Cure and The Stephen M. Coffman Charitable Trust. In July 2011, these non-profit organizations came together to jointly fund a $100,000 research grant to University of California Los Angeles (UCLA) neurosurgeon Linda Liau, M.D., PhD to begin this clinical trial, Optimizing Dendritic Cell Vaccination for Low Grade Glioma Patients. This is the first trial of its kind for patients that have been diagnosed with low grade gliomas, a common form of brain cancer. This research has the potential to improve the lives of brain cancer patients.